Bertolini S, Elicio N, Cordera R, Gapitanio G L, Montagna G, Croce S, Saturnino M, Balestreri R, De Cecco L
Department of Internal Medicine, University of Genoa, Italy.
Acta Obstet Gynecol Scand. 1987;66(4):327-32. doi: 10.3109/00016348709103647.
Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG). These preparations were studied for six treatment cycles. Total cholesterol and apoprotein B did not change in any group. Low density lipoprotein (LDL) cholesterol was significantly decreased in the groups of women treated with M-DSG and T-GSD respectively. No changes were observed in the T-LNG group. With M-DSG, significant increases were observed in high-density lipoprotein (HDL) cholesterol and HDL3 cholesterol, whilst HDL2 cholesterol did not change. With both T-GSD and T-LNG, no changes were observed in HDL cholesterol, whilst a significant increase in HDL3 cholesterol together with a trend to decrease in HDL2 cholesterol were observed. Apolipoprotein AI increased with the following ranking M-DSG greater than T-GSD greater than T-LNG. The LDL/HDL cholesterol ratio significantly decreased with both M-DSG and T-GSD. In the T-LNG group there was no change in this ratio. Triglycerides increased to the same extent in all treatment groups. As far as concerns the risk of arterial diseases, these three oral contraceptive formulations mostly induced negligible and/or partly favorable changes in plasma lipids and lipoproteins; however, the lipoprotein pattern during M-DSG treatment resulted better than during T-GSD, and the latter turned out to be better than during T-LNG.
对60名健康女性研究了三种口服避孕药制剂。这项随机、对照、基线对照研究旨在调查这些制剂对血浆脂质和脂蛋白的影响。研究了以下配方：一种含炔雌醇和去氧孕烯的单相制剂（M-DSG）以及两种分别含炔雌醇和孕二烯酮或左炔诺孕酮的三相制剂（T-GSD和T-LNG）。对这些制剂进行了六个治疗周期的研究。所有组的总胆固醇和载脂蛋白B均未改变。分别接受M-DSG和T-GSD治疗的女性组中，低密度脂蛋白（LDL）胆固醇显著降低。T-LNG组未观察到变化。使用M-DSG时，高密度脂蛋白（HDL）胆固醇和HDL3胆固醇显著升高，而HDL2胆固醇未改变。使用T-GSD和T-LNG时，HDL胆固醇均未改变，但HDL3胆固醇显著升高，同时HDL2胆固醇有下降趋势。载脂蛋白AI升高，顺序如下：M-DSG大于T-GSD大于T-LNG。M-DSG和T-GSD治疗后，LDL/HDL胆固醇比值均显著降低。T-LNG组该比值无变化。所有治疗组的甘油三酯均升高至相同程度。就动脉疾病风险而言，这三种口服避孕药制剂大多在血浆脂质和脂蛋白方面引起可忽略不计和/或部分有利的变化；然而，M-DSG治疗期间的脂蛋白模式优于T-GSD治疗期间，而T-GSD治疗期间又优于T-LNG治疗期间。
